US 12,187,772 B2
IL10 agonists and methods of use thereof
Jie Dai, Yorktown Heights, NY (US); Maria del Pilar Molina-Portela, Bronx, NY (US); Ella Ioffe, Bronx, NY (US); and Markus Mohrs, Pleasantville, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Apr. 28, 2023, as Appl. No. 18/308,892.
Application 18/308,892 is a continuation of application No. 17/317,475, filed on May 11, 2021, granted, now 11,673,930.
Claims priority of provisional application 63/023,703, filed on May 12, 2020.
Prior Publication US 2023/0279070 A1, Sep. 7, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/20 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 1/22 (2006.01); C07K 14/54 (2006.01); C07K 16/42 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/5428 (2013.01) [A61K 38/2066 (2013.01); A61K 47/68 (2017.08); A61K 47/6889 (2017.08); A61P 35/00 (2018.01); C07K 1/22 (2013.01); C07K 16/42 (2013.01); A61K 38/00 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2319/30 (2013.01)] 31 Claims
OG exemplary drawing
 
1. A method of treating cancer, the method comprising administering to a subject in need thereof:
(a) an IL10 agonist which comprises an amino acid sequence having at least 95% sequence identity to any one of SEQ ID NOS: 34, 37, and 38 and lacks an antibody variable region; and
(b) an anti-PD1 antibody.